Journal
CANCER RESEARCH
Volume 79, Issue 4, Pages 819-829Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-18-1273
Keywords
-
Categories
Funding
- NIH [CCSG CA016672, R01 CA211615, U01 CA201777]
- Cancer Prevention and Research Institutes of Texas [RP160710]
- University of Texas MD Anderson-China Medical University
- Hospital Sister Institution Fund
- Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence [MOHW107-TDU-B-212-114024, MOHW107-TDU-B-212-112015]
- Center for Biological Pathways
- National Key Research and Development Program of China [2017YFC1308604]
Ask authors/readers for more resources
PARP1 inhibitors (PARPi) are currently used in the clinic for the treatment of ovarian and breast cancers, yet their therapeutic efficacy against hepatocellular carcinoma (HCC) has been disappointing. To ensure therapeutic efficacy of PARPi against HCC, a disease often diagnosed at intermediate to advanced stages with no effective treatment options, it is critical to identify not only biomarkers to predict PARPi resistance but also rational treatments to overcome this. Here, we report that a heterodimer of EGFR and MET interacts with and phosphorylates Y907 of PARP1 in the nucleus, which contributes to PARPi resistance. Inhibition of both EGFR and MET sensitized HCC cells to PARPi, and both EGFR and MET are known to be overexpressed in HCC. This report provides an explanation for the poor efficacy of PARPi against HCC and suggests combinatorial treatment consisting of EGFR, MET, and PARP inhibitors may be an effective therapeutic strategy in HCC. Significance: Regulation of PARP by the c-MET and EGFR heterodimer suggests a potentially effective combination therapy to sensitize HCC to PARPi.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available